Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Haifa Shen M.D. Ph.D.

Haifa Shen, M.D., Ph.D.

Haifa Shen, M.D., Ph.D.

Haifa Shen M.D., Ph.D.

Assistant Member
Department of Nanomedicine
The Methodist Hospital Research Institute
Assistant Professor
Department of Cell and Developmental Biology
Weill Cornell Medical College

E-mail: hshen@houstonmethodist.org
Phone: 713-441-7321


M.D. Zhejiang University Medical School, Hangzhou, China
Ph.D. The University of Texas at Houston, Graduate School of Biomedical Sciences

Postdoctoral Training

Postdoctoral Fellow, National Cancer Institute, Frederick, MD


Dr. Shen earned his M.D. from Zhejiang University Medical School of Hangzhou, China in 1985, and his Ph. D. from the University of Texas at Houston in 1997. After completing a four-year postdoctoral fellowship at the National Cancer Institute, he worked on drug development at Lexicon Pharmaceuticals. He returned to the University of Texas at Houston Medical School as an assistant professor before becoming a member of The Methodist Hospital Research Institute in 2010.

Description of Research

Dr. Shen’s research interest is in the development of cancer therapeutics. His research approach combines drug chemistry and formulation, nanotechnology, and cancer biology. His research team has developed porous silicon microparticle-based drug carriers to specifically deliver chemotherapy drugs and gene-silencing agents such as siRNA and microRNA to tumor tissues for effective treatment of breast cancer, ovarian cancer, and pancreatic cancer. They have also successfully developed immune therapy for cancer prevention and treatment.

Major Areas of Research

Drug delivery, experimental cancer therapy, cancer vaccine, and nanotechnology

Recent Publications

1. XBP1 promotes triple-negative breast cancer by controlling the HIF1a pathway.
Chen X, Iliopoulos D, Zhang Q, Tang Q, Greenblatt MB, Hatziapostolou M, Lim E, Tam WL, Ni M, Chen Y, Mai J, Shen H, Hu DZ, Adoro S, Hu B, Song M, Tan C, Landis MD, Ferrari M, Shin SJ, Brown M, Chang JC, Liu XS, Glimcher LH. Nature. 2014 Apr 3;508(7494):103-7. doi: 10.1038/nature13119. Epub 2014 Mar 23.

2. Multifunctional Gold Nanorods for siRNA Gene Silencing and Photothermal Therapy.
Shen J, Kim HC, Mu C, Gentile E, Mai J, Wolfram J, Ji LN, Ferrari M, Mao ZW, Shen H. Adv Healthc Mater. 2014 Apr 1. doi: 10.1002/adhm.201400103. [Epub ahead of print]

3. Transport properties of pancreatic cancer describe gemcitabine delivery and response.
Koay EJ, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, Kang Y, Bhosale PR, Tamm EP, Crane CH, Javle M, Katz MH, Gottumukkala VN, Rozner MA, Shen H, Lee JE, Wang H, Chen Y, Plunkett W, Abbruzzese JL, Wolff RA, Varadhachary GR, Ferrari M, Fleming JB. J Clin Invest. 2014 Apr 1;124(4):1525-36. doi: 10.1172/JCI73455. Epub 2014 Mar 10.

4. Polyarginine Induces an Antitumor Immune Response through Binding to Toll-Like Receptor 4.
Yang Y, Wolfram J, Fang X, Shen H, Ferrari M. Small. 2014 Apr;10(7):1250-4. doi: 10.1002/smll.201302887. Epub 2013 Dec 10.

5. Evaluation of anticancer activity of celastrol liposomes in prostate cancer cells.
Wolfram J, Suri K, Huang Y, Molinaro R, Borsoi C, Scott B, Boom K, Paolino D, Fresta M, Wang J, Ferrari M, Celia C, Shen H. J Microencapsul. 2014 Mar 24. [Epub ahead of print]

6. Transient mild hyperthermia induces E-selectin mediated localization of mesoporous silicon vectors in solid tumors.
Kirui DK, Mai J, Palange AL, Qin G, van de Ven AL, Liu X, Shen H, Ferrari M. PLoS One. 2014 Feb 18;9(2):e86489. doi: 10.1371/journal.pone.0086489. eCollection 2014.

7. Cyclodextrin and Polyethylenimine Functionalized Mesoporous Silica Nanoparticles for Delivery of siRNA Cancer Therapeutics.
Shen J, Kim HC, Su H, Wang F, Wolfram J, Kirui D, Mai J, Mu C, Ji LN, Mao ZW, Shen H. Theranostics. 2014 Feb 15;4(5):487-97. doi: 10.7150/thno.8263. eCollection 2014.

8. Shrinkage of pegylated and non-pegylated liposomes in serum.
Wolfram J, Suri K, Yang Y, Shen J, Celia C, Fresta M, Zhao Y, Shen H, Ferrari M. Colloids Surf B Biointerfaces. 2014 Feb 1;114:294-300. doi: 10.1016/j.colsurfb.2013.10.009. Epub 2013 Oct 24.

9. Polycation-functionalized nanoporous silicon particles for gene silencing on breast cancer cells.
Zhang M, Xu R, Xia X, Yang Y, Gu J, Qin G, Liu X, Ferrari M, Shen H.Biomaterials. 2014 Jan;35(1):423-31. doi: 10.1016/j.biomaterials.2013.09.033. Epub 2013 Oct 5.

10. Circulating proteolytic products of carboxypeptidase N for early detection of breast cancer.
Li Y, Li Y, Chen T, Kuklina AS, Bernard P, Esteva FJ, Shen H, Ferrari M, Hu Y.Clin Chem. 2014 Jan;60(1):233-42. doi: 10.1373/clinchem.2013.211953. Epub 2013 Oct 21.

11. An IKKa-nucleophosmin axis utilizes inflammatory signaling to promote genome integrity.
Xia X, Liu S, Xiao Z, Zhu F, Song NY, Zhou M, Liu B, Shen J, Nagashima K, Veenstra TD, Burkett S, Datla M, Willette-Brown J, Shen H, Hu Y.Cell Rep. 2013 Dec 12;5(5):1243-55. doi: 10.1016/j.celrep.2013.10.046. Epub 2013 Nov 27.

12. Live-cell single-molecule imaging reveals clathrin and caveolin-1 dependent docking of SMAD4 at the cell membrane.
Yang Y, Wolfram J, Shen J, Zhao Y, Fang X, Shen H, Ferrari M.FEBS Lett. 2013 Dec 11;587(24):3912-20. doi: 10.1016/j.febslet.2013.10.041. Epub 2013 Nov 6.

13. High capacity nanoporous silicon carrier for systemic delivery of gene silencing therapeutics.
Shen J, Xu R, Mai J, Kim HC, Guo X, Qin G, Yang Y, Wolfram J, Mu C, Xia X, Gu J, Liu X, Mao ZW, Ferrari M, Shen H.ACS Nano. 2013 Nov 26;7(11):9867-80. doi: 10.1021/nn4035316. Epub 2013 Oct 18.

14. Estrogen receptor a regulates ATM Expression through miRNAs in breast cancer.
Guo X, Yang C, Qian X, Lei T, Li Y, Shen H, Fu L, Xu B.Clin Cancer Res. 2013 Sep 15;19(18):4994-5002. doi: 10.1158/1078-0432.CCR-12-3700. Epub 2013 Jul 15.

15. Mesoporous silica coating on carbon nanotubes: layer-by-layer method.
Deng X, Qin P, Luo M, Shao E, Zhao H, Yang X, Wang Y, Shen H, Jiao Z, Wu M.Langmuir. 2013 Jun 11;29(23):6815-22. doi: 10.1021/la400690p. Epub 2013 May 28.

16. Delivery of gene silencing agents for breast cancer therapy.
Shen H, Mittal V, Ferrari M, Chang J.Breast Cancer Res. 2013 May 8;15(3):205. [Epub ahead of print]

17. Identification of an inhibitory mechanism of luteolin on the insulin-like growth factor-1 ligand-receptor interaction.
Yang Y, Shen J, Yu X, Qin G, Zhang M, Shen H, Mao Z, Ferrari M.Chembiochem. 2013 May 27;14(8):929-33. doi: 10.1002/cbic.201300082. Epub 2013 Apr 29.

18. Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery.
Shen H, Rodriguez-Aguayo C, Xu R, Gonzalez-Villasana V, Mai J, Huang Y, Zhang G, Guo X, Bai L, Qin G, Deng X, Li Q, Erm DR, Aslan B, Liu X, Sakamoto J, Chavez-Reyes A, Han HD, Sood AK, Ferrari M, Lopez-Berestein G.Clin Cancer Res. 2013 Apr 1;19(7):1806-15. doi: 10.1158/1078-0432.CCR-12-2764. Epub 2013 Feb 5.

19. Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy.
Xu R, Huang Y, Mai J, Zhang G, Guo X, Xia X, Koay EJ, Qin G, Erm DR, Li Q, Liu X, Ferrari M, Shen H.Small. 2013 May 27;9(9-10):1799-808. doi: 10.1002/smll.201201510. Epub 2013 Jan 6.

20. Serum peptidomic biomarkers for pulmonary metastatic melanoma identified by means of a nanopore-based assay.
Fan J, Huang Y, Finoulst I, Wu HJ, Deng Z, Xu R, Xia X, Ferrari M, Shen H, Hu Y.Cancer Lett. 2013 Jul 1;334(2):202-10. doi: 10.1016/j.canlet.2012.11.011. Epub 2012 Nov 27.

21. Nanovector delivery of siRNA for cancer therapy.
Shen H, Sun T, Ferrari M.Cancer Gene Ther. 2012 Jun;19(6):367-73. doi: 10.1038/cgt.2012.22. Epub 2012 May 4. Review.